Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.99M | 4.44M | 4.54M | 3.95M | 2.39M |
| Gross Profit | -3.99M | -4.44M | -4.54M | -3.95M | -2.39M |
| SG&A Expenses | 1.97M | 1.93M | 1.94M | 1.63M | 1.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.97M | 6.37M | 6.48M | 5.58M | 3.70M |
| Operating Income | -5.97M | -6.37M | -6.48M | -5.58M | -3.70M |
| Income Before Tax | -5.80M | -5.58M | -6.08M | -4.36M | -6.62M |
| Income Tax Expenses | 19.00K | 32.00K | 63.00K | -- | -- |
| Earnings from Continuing Operations | -5.82M | -5.61M | -6.14M | -4.36M | -6.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.82M | -5.61M | -6.14M | -4.36M | -6.62M |
| EBIT | -5.97M | -6.37M | -6.48M | -5.58M | -3.70M |
| EBITDA | -5.96M | -6.37M | -6.48M | -5.57M | -3.70M |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.04 | -0.06 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.04 | -0.04 | -0.06 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 167.34M | 171.23M | 165.82M | 120.50M | 113.03M |
| Average Diluted Shares Outstanding | 167.34M | 171.23M | 165.82M | 120.50M | 113.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |